

Commemorating the Duchossois Family's Partnership with the UCCCC

Leon Jacobson, MD, uses the first chemotherapeutic agent, nitrogen mustard, to treat leukemia and lymphoma.

John Ultmann, MD, coordinates the University's successful application to the National Cancer Institute (NCI) for creation of the University of Chicago Cancer Research Center (UCCRC) and becomes its first director

Harvey Golomb, MD, is among the first physicians in the world to perform clinical studies using interferon, the first of a series of naturally produced substances that can boost the patient's own immune system as a weapon against cancer, and becomes a world-class expert in hairy cell leukemia.



Led by Olufunmilayo Olopade, MD, FACP, the Cancer Risk Clinic is established. The clinic helps high-risk individuals learn how to reduce the risk of cancer due to family history, medical and genetic conditions, and lifestyle factors.

The Duchossois family pledges \$1 million to further invest in Dr. Ultmann's cancer research efforts and to build the Beverly Duchossois Cancer Laboratories



The Duchossois Center for Advanced Medicine, designed with the outpatient's best interests in mind, opens its doors.

The Cancer Research Center is renamed the University of Chicago Comprehensive Cancer Center

The Ludwig Fund for Cancer Research donates \$50 million to create the Ludwig Center for Metastasis Research at the University of Chicago—under the leadership of Drs. Greene and Weichselbaum-which focuses on basic mechanisms of metastasis and novel therapeutic approaches.

(UCCCC). The name reflects the growth in scope of its programs.

The Duchossois family, long-time champions of science and medicine at the University of Chicago, donates \$10 million to support cancer research and the study of metastasis. Members of the Duchossois family were made Honorary Fellows of the University's Biological Sciences Division, an honor that recognizes leaders who have a lasting impact on science and medicine at the University.

Dr. Olopade leads a Specialized Program of Research Excellence (SPORE) team to develop genetic and imaging-based approaches to the prevention, detection, and treatment of breast cancer in women who are at increased risk of developing an aggressive form of breast cancer at a young age.

The Beverly Duchossois Cancer

other medical specialties.

Laboratories are relocated to the newly

opened Gwen and Jules Knapp Center for

Biomedical Discovery, a state-of-the-art

programs in children's health, cancer, and

facility that houses translational research



Craig and Janet Duchossois and The Duchossois Family Foundation make a transformational \$100 million gift to establish the Duchossois Family Institute, which is developing a "new science of wellness", aimed at preserving health and complementing medicine's traditional focus on disease treatment. The Institute is accelerating research and interventions based on how the human immune system, microbiome and genetics interact to maintain health.

- 2021

Ashley Joyce joins the University of Chicago Medical Center Board of Trustees. In this role, she champions the highest priorities of the Medical Center, including the strategic vision for the Comprehensive Cancer Center.

The Ben May Institute for Cancer Research is formally established with funds provided by Alabama businessman and philanthropist Ben May. Charles Huggins, MD, becomes its first director

The Duchossois family makes its first gift to support Dr. Ultmann and cancer research at the University of



Michelle Le Beau, PhD, and Janet Rowley, MD, recognize that therapy-related acute myeloid leukemia (t-AML) is characterized by the loss of chromosomes 5 and 7, thereby implicating tumor suppressor genes in the pathogenesis of leukemia.

The Duchossois family gives \$21 million to name the Duchossois Center for Advanced Medicine (DCAM) and to establish the John Ultmann



Ralph Weichselbaum, MD, and Samuel Hellman, MD, propose that there is an intermediate state between cancer that has not spread at all and cancer that has spread extensively. They name this phenomenon "oligometastases," meaning cancer that has spread to a few distant sites.

Kunio Doi, PhD, brings the first computer-assisted system to read mammograms into clinical use.

Duchossois family and the American Cancer Society, the University of Chicago Cancer Resource Center moves to a central location in the DCAM lobby to allow easy access to the breadth of resources and support programs available for cancer patients, families, and caregivers.

In partnership with the

The University of Chicago Medical Center is the first in Illinois to acquire "Brilliance iCT,"a 256-slice "wide-area" computed tomography scanner, with four times the capacity of the previous generation of multi-slice scanners that produces extremely highresolution images with reduced radiation exposure.

The National Cancer Institute designates Chicago as a "Comprehensive Cancer Center," in recognition of the Center's excellence in basic, clinical, and population research. The University of Chicago Comprehensive Cancer Center is one of just 56 Comprehensive Centers nationally.

Dr. Geoffrey Greene, PhD,

tamoxifen blocks the effects

discovers the molecular

mechanism by which

of estrogen.

Megan McNerney, MD, PhD, and

Kevin White, PhD, clone CUX1, a long-sought tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

Ludwig Cancer Research donates an Research, building on critical Duchossois

The National Cancer Institute awarded the University of Chicago an exclusive \$36 million contract to develop the first Cancer Genomics Data Commons. The Data Commons will pool the vast store of genomic data gathered from independent studies around the world into one data management infrastructure, and make possible the ability to catalog most, if not all, of the genomic changes associated with cancer.

2023

DFI GMP facility opens, making UChicago the first academic institution to have clinical manufacturing capabilities embedded with a microbiome research center. Manufacturing drugs on-site for use in clinical trials will accelerate the timeline from discovery to therapeutic application, benefiting patients across disease types.

DFI Director Eric Pamer, MD, identifies patterns of microbiota disruption that occur in cancer patients during hematopoieticcell transplant and determined how to use these patterns as predictors of outcome following transplantation.

2020

The University of Chicago Campaign for Inquiry and Impact concludes, raising \$5.43 billion. The Medical Center's campaign, co-chaired by Craig Duchossois, raised \$1.185B to support pioneering scholarship, transformative education, and world-class patient care.

2013

additional \$90 million to the University of Chicago Ludwig Center for Metastasis family investments in metastasis.